Institut Català d'Oncologia, Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Broadstreet HEOR, Vancouver, BC, Canada.
Future Oncol. 2024;20(36):2855-2868. doi: 10.1080/14796694.2024.2393566. Epub 2024 Sep 13.
Characterize the logistical challenges faced by healthcare professionals (HCPs), patients and caregivers during the chimeric antigen receptor T-cell (CAR T) treatment process for non-Hodgkin lymphoma patients. HCPs in the US and UK experienced with CAR T administration participated in interviews and completed a web-based survey. A total of 133 (80 US, 53 UK) HCPs participated. Two or more logistical challenges were identified by ≥60% of respondents across all stages of the CAR T process. Commonly reported challenges were lengthy waiting periods, administrative and payer-related barriers, limited healthcare capacity, caregiver support and (particularly in the US) patient out-of-pocket costs. The CAR T treatment process presents numerous challenges, highlighting an unmet need for more convenient therapies.
描述医疗保健专业人员（HCP）、患者和护理人员在接受嵌合抗原受体 T 细胞（CAR T）治疗非霍奇金淋巴瘤患者过程中所面临的后勤挑战。参与 CAR T 管理的美国和英国 HCP 参加了访谈并完成了基于网络的调查。共有 133 名（80 名美国，53 名英国）HCP 参与。在 CAR T 过程的所有阶段，有≥60%的受访者确定了两个或更多的后勤挑战。常见的报告挑战包括漫长的等待期、行政和支付方相关障碍、有限的医疗保健能力、护理人员支持以及（特别是在美国）患者自付费用。CAR T 治疗过程带来了诸多挑战，突显了对更便捷疗法的未满足需求。
